Bearish
Johnson & Johnson's stock drops 5.7% amid Q3 earnings and MedTech sales miss
Johnson & Johnson's stock declined by 5.7% following its third-quarter earnings report, which revealed a 2.5% rise in medical technology sales that fell short of Wall Street expectations. The company also announced a potential spinoff of its DePuy Synthes orthopedics unit. Despite these challenges, J&J raised its full-year revenue and adjusted EPS guidance, driven by strong performance in its Innovative Medicine division.
Key points
- MedTech sales growth of 2.5% misses expectations, leading to a 5.7% stock decline.
- Potential spinoff of DePuy Synthes orthopedics unit announced.
- Full-year revenue and adjusted EPS guidance raised, bolstered by Innovative Medicine's strong performance.
Sources
AI-generated from public news sources. Not financial advice.
